These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28889246)

  • 21. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
    Montgomery RM; Queiroz Lde S; Rogerio F
    Arq Neuropsiquiatr; 2015 Jul; 73(7):561-8. PubMed ID: 26200049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with increased survival after surgical resection of glioblastoma in octogenarians.
    Abdullah KG; Ramayya A; Thawani JP; Macyszyn L; Martinez-Lage M; O'Rourke DM; Brem S
    PLoS One; 2015; 10(5):e0127202. PubMed ID: 25978638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
    Park JE; Kim HS; Park SY; Nam SJ; Chun SM; Jo Y; Kim JH
    Radiology; 2020 Feb; 294(2):388-397. PubMed ID: 31845844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.
    Blasel S; Vorwerk R; Kiyose M; Mittelbronn M; Brunnberg U; Ackermann H; Voss M; Harter PN; Hattingen E
    J Neurol; 2018 Mar; 265(3):647-658. PubMed ID: 29383512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D; Xing Z; Cao D
    J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
    Fudaba H; Momii Y; Matsuta H; Onishi K; Kawasaki Y; Sugita K; Shimomura T; Fujiki M
    World Neurosurg; 2021 May; 149():e469-e480. PubMed ID: 33567368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
    Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
    J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
    Suh CH; Kim HS; Paik W; Choi C; Ryu KH; Kim D; Woo DC; Park JE; Jung SC; Choi CG; Kim SJ
    Radiology; 2019 Jun; 291(3):752-762. PubMed ID: 30990380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Machine-learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time.
    Liao X; Cai B; Tian B; Luo Y; Song W; Li Y
    J Cell Mol Med; 2019 Jun; 23(6):4375-4385. PubMed ID: 31001929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.